TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, announces today its intention to broaden its market reach through a recently filed application for listing on the OTCQB® Venture Market (the “OTCQB”) in the United States. Listing on the OTCQB is subject to approval of the OTC Markets Group.
The OTCQB, a reputable U.S. trading platform operated by OTC Markets Group Inc., serves as a pivotal gateway for both domestic and international companies aiming to bolster their visibility and accessibility to American investors. By maintaining stringent standards for transparency and compliance, the OTCQB fosters an environment conducive to informed trading, thus enhancing opportunities for companies to attract investment and optimize shareholder value.
The Company is delighted to announce that it has also applied for DTC eligibility by the Depository Trust Company (“DTC“) for its shares on the OTCQB venture market. Approval for DTC eligibility will expand the Company’s stock reach to a wider audience of potential investors and brokerage firms that mandate additional compliance measures. This move aims to enhance accessibility and potentially boost liquidity through online transactions.